News | May 11, 2022
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
At an affordable price, a researcher can process fresh samples of 10,000 cells immediately with a stable stopping point within two hours, simplifying sample management at the laboratory and limiting transcriptional changes
This RT-PCR diagnostic kit helps in diagnosis of AS by detecting HLAB27 gene
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
New kit enhances menu of FFPE solutions and allows oncology researchers to extract higher yields of concentrated DNA compared to traditional techniques
The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
The survey indicates that 30% of people are still feeling depressed or hopeless on a few days as against GOQii’s last year survey on mental Health where 43% of Indians were depressed
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Inconsistent antibody performance is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research
Subscribe To Our Newsletter & Stay Updated
